MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Fermé

SecteurSoins de santé

13.24 0.61

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.01

Max

13.24

Chiffres clés

By Trading Economics

Revenu

1.5B

14B

Ventes

3.4B

84B

P/E

Moyenne du Secteur

17.587

63.778

BPA

16.936

Rendement du dividende

0.72

Marge bénéficiaire

16.795

Employés

27,048

EBITDA

2.4B

24B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+38.3% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.72%

2.39%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

8.8B

11B

Ouverture précédente

12.63

Clôture précédente

13.24

Score Technique

By Trading Central

Confiance

Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 juin 2024, 13:33 UTC

Acquisitions, Fusions, Rachats

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update

26 juin 2024, 12:32 UTC

Acquisitions, Fusions, Rachats

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million

25 avr. 2024, 10:32 UTC

Résultats

Nestle India Reports Rise in Quarterly Profit, Announces JV With Dr. Reddy's Laboratories

23 janv. 2025, 17:46 UTC

Résultats

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23 janv. 2025, 17:42 UTC

Résultats

Dr. Reddy's 3Q Rev INR83.59B

5 nov. 2024, 11:01 UTC

Résultats

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5 nov. 2024, 11:00 UTC

Résultats

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5 nov. 2024, 10:57 UTC

Résultats

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5 nov. 2024, 10:57 UTC

Résultats

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

26 juin 2024, 11:54 UTC

Acquisitions, Fusions, Rachats

Haleon: All Other 2024 Guidance Unchanged

26 juin 2024, 11:54 UTC

Acquisitions, Fusions, Rachats

Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%

26 juin 2024, 11:52 UTC

Acquisitions, Fusions, Rachats

Haleon: Sale Allow For NRT Exit Outside US, Trims Business Complexity

26 juin 2024, 11:51 UTC

Acquisitions, Fusions, Rachats

Haleon: Deal Expected to Complete Early 4Q

26 juin 2024, 11:50 UTC

Acquisitions, Fusions, Rachats

Haleon: Use of Proceeds Will Be in Line With Capital Allocation Priorities

26 juin 2024, 11:49 UTC

Acquisitions, Fusions, Rachats

Haleon: Deal Structure Upfront Cash GBP458M, GBP42M Performance-Based Payable

26 juin 2024, 11:48 UTC

Acquisitions, Fusions, Rachats

Haleon: Portfolio Includes Nicotinell, Nicabate, Habitrol and Thrive Available in Gum, Lozenge

26 juin 2024, 11:47 UTC

Acquisitions, Fusions, Rachats

Haleon: Deal Worth GBP500M With Additional Proceeds From Inventory Transfer

26 juin 2024, 11:46 UTC

Acquisitions, Fusions, Rachats

Haleon to Sell Non-US Nicotine Replacement Therapy Business to Dr. Reddy's Laboratories

7 mai 2024, 10:56 UTC

Résultats

Dr. Reddy's Laboratories 4Q Net INR13.07B Vs. Net INR9.59B >500124.BY

7 mai 2024, 10:55 UTC

Résultats

Dr. Reddy's Laboratories 4Q Rev INR70.83B Vs. INR62.97B >500124.BY

Comparaison

Variation de prix

Dr Reddy's Laboratories Ltd-ADR prévision

Objectif de Prix

By TipRanks

38.3% hausse

Prévisions sur 12 Mois

Moyen 18.2 USD  38.3%

Haut 19.4 USD

Bas 17 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

13.12 / 13.21Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.